Milestone Scientific (MLSS) Q4 2025 earnings review
Cost Cuts Narrow Losses, But Dwindling Cash Leaves No Margin for Error
Milestone Scientific is attempting a turnaround under new CEO Eric Hines, who took over in August 2025. The immediate focus has been triage: slashing R&D and SG&A to reign in operating losses, which improved by $1.1M for the full year. While top-line growth was a modest 4% in FY25, management is guiding for double-digit expansion in FY26, heavily reliant on a projected 400% surge in CompuFlo medical sales. However, the balance sheet flashes red. With only $1.1M in cash and a Q4 operating loss that matched that exact figure, the company is in a race against time to hit its early-2027 breakeven target without highly dilutive capital raises.
🐂 Bull Case
The new leadership team is aggressively trimming the fat. Total operating expenses fell by over $1M in FY25, pulling the operating loss down with it. Management is scrutinizing every expense for measurable ROI.
CompuFlo is finally moving from a developmental project to commercialization. Guidance of $500K-$600K in FY26 represents a 400% jump, signaling real traction in clinical adoption and VA channel penetration.
🐻 Bear Case
The company ended the year with just $1.1M in cash, down from $3.2M a year ago. Achieving cash flow breakeven by early 2027 seems mathematically impossible without an interim capital injection or debt facility.
While international dental sales grew, the U.S. domestic dental market—the company's supposed foundation—contracted by 7% year-over-year.
⚖️ Verdict: 🔴
Bearish. Management's cost-cutting efforts and focus on commercialization are commendable and necessary. However, a $1.1M cash balance combined with a $5.7M annual operating loss creates an imminent liquidity risk that overshadows the growth narrative.
Key Themes
Severe Liquidity Constraints
Cash and cash equivalents plummeted to $1.1M at the end of FY25, down from $3.2M in FY24. While management states they are avoiding raising capital 'simply to fund inefficient practices,' the reality is stark: Q4 operating loss was $1.1M. Even with targeted structural cost reductions, bridging the gap to the 'early 2027' breakeven target will require near-perfect execution on working capital or external financing.
Aggressive Cost Restructuring
The operational pivot under CEO Eric Hines is evident in the expense lines. Selling, general, and administrative (SG&A) expenses were cut by roughly $700K (down to $11.5M), and R&D was nearly halved (down to $449K). This right-sizing drove the $1.1M improvement in annual operating loss and provides the leverage needed to make future revenue growth impactful to the bottom line.
Domestic Dental Market Decelerating
Despite management calling the dental business the 'foundation of our company,' U.S. domestic dental sales declined 7% year-over-year. This deceleration in their home market forces an over-reliance on international distributors and unproven medical products to drive top-line numbers.
International Dental Resiliency
International dental sales accelerated, growing 9% year-over-year. This overseas momentum successfully offset the domestic slump, allowing total product sales to grind out a 4% overall gain for the year. Registrations in Japan, India, and Mexico for the STA system could fuel this further.
Gross Margin Compression
Revenue grew by $344K in FY25, but Gross Profit remained entirely flat at $6.4M. This indicates a reversing trend in profitability metrics, with gross margins compressing from 74.6% in 2024 to 71.4% in 2025. Management attributed this to changes in product mix and cost structure, signaling that the growth currently being captured is lower margin.
CompuFlo and DPS Technology Commercialization
Milestone is finally shifting its proprietary DPS Dynamic Pressure Sensing Technology from a research focus to a commercial one. By targeting epidural injections via the CompuFlo system, the company is tapping into a significant medical market. The launch of the CompuFlo advisor program with over ten physician partners aims to drive clinical adoption and secure crucial reimbursement pathways.
Other KPIs
This represents an improvement of $963,000 (roughly 47%) compared to the $2.0 million loss in the prior year period. This sequential and year-over-year tightening demonstrates that the structural expense cuts implemented in the second half of 2025 are taking immediate effect.
Worsened from a net loss of $4.7 million in 2024. However, this is purely a product of base effects: 2024 results included a one-time $1.98 million gain from the sale of net operating losses. On a pure operational basis, the core deficit shrank.
Inventory remains stable (up slightly from $3.71M in 2024) and makes up more than half of the company's total current assets. Liquidating this inventory efficiently will be the primary mechanism to fund operations given the low cash reserves.
Guidance
Accelerating. The midpoint of $10.0M implies an 11.5% YoY growth rate, a stark acceleration from the 4% growth achieved in FY25. This is predicated on broadening commercial adoption in both dental and medical segments.
Accelerating. Management expects an approximate 400% increase over 2025, which mathematically implies FY25 CompuFlo sales were a paltry $100K - $120K. Hitting this target is essential to prove the medical division has a viable commercial future.
Key Questions
Bridging the Cash Gap
With $1.1 million in cash, $800,000 in convertible debt, and a target of cash flow breakeven in early 2027, how exactly does the company plan to fund operations for the next 12-15 months without raising equity?
Domestic Dental Autopsy
What specific competitive pressures or macro factors drove the 7% decline in U.S. domestic dental sales, and what concrete steps are being taken to stabilize this foundational market?
Gross Margin Trajectory
Given the 320 basis point compression in gross margins during FY25 due to product mix, will the anticipated 400% growth in CompuFlo sales act as a margin accretive or dilutive force in FY26?